

1 **Title:** Is COVID-19 seasonal? A time series modeling approach

2 **Running Title:** COVID-19 seasonality

3 **Authors:** Timothy L Wiemken Ph.D., Farid Khan MPH, Jennifer L Nguyen ScD, Luis Jodar

4 Ph.D., John M McLaughlin PhD

5 **Affiliations:** Pfizer Inc. 500 Arcola Rd. Collegeville, PA 19426 USA

6 **Corresponding Author:**

7 Timothy L Wiemken Ph.D. MPH

8 Global Clinical Epidemiologist

9 Pfizer Vaccines

10 500 Arcola Rd.

11 Collegeville, PA 19426 USA

12 Phone: 314-285-7286

13 Email: [timothy.wiemken@pfizer.com](mailto:timothy.wiemken@pfizer.com)

14 **Alternate Corresponding Author:**

15 John M McLaughlin, PhD

16 Vice President, Global Franchise Lead, COVID-19 and mRNA vaccines

17 Pfizer Inc.

18 500 Arcola Rd

19 Collegeville, PA 19426

20 E: [john.mclaughlin@pfizer.com](mailto:john.mclaughlin@pfizer.com)

21

22 **Key Words:** SARS-CoV-2, winter, fall, autumn, surge

23

24 **Summary of the Main Point (38/40 Words)**

25 Although SARS-CoV-2 continues to cause morbidity and mortality year-round due to its high  
26 transmissibility and rapid viral evolution, our results suggest that COVID-19 activity in the  
27 United States and Europe peaks during the traditional winter viral respiratory season.

28

29

30 **ABSTRACT (248/250 words)**

31 *Background*

32 Determining whether SARS-CoV-2 is or will be seasonal like other respiratory viruses is critical  
33 for public health planning, including informing vaccine policy regarding the optimal timing for  
34 deploying booster doses. To help answer this urgent public health question, we evaluated  
35 whether COVID-19 case rates in the United States and Europe followed a seasonal pattern using  
36 time series models.

37

38 *Methods*

39 We analyzed COVID-19 data from Our World in Data from Mar 2020 through Apr 2022 for the  
40 United States (and Census Region) and five European countries (Italy, France, Germany, Spain,  
41 and the United Kingdom). For each, anomalies were identified using Twitter's decomposition  
42 method and Generalized Extreme Studentized Deviate tests. We performed sensitivity analyses  
43 to determine the impact of data source (i.e., using US Centers for Disease Control and Prevention  
44 [CDC] data instead of OWID) and whether findings were similar after adjusting for multiple  
45 covariates. Finally, we determined whether our time series models accurately predicted seasonal  
46 influenza trends using US CDC FluView data.

47

48 *Results*

49 Anomaly plots detected COVID-19 rates that were higher than expected between November and  
50 March each year in the United States and Europe. In the US Southern Census Region, in addition  
51 to seasonal peaks in the fall/winter, a second peak in Aug/Sep 2021 was identified as anomalous.  
52 Results were robust to sensitivity analyses.

53

54 *Conclusions*

55 Our results support employing annual protective measures against SARS-CoV-2 such as

56 administration of seasonal booster vaccines or other non-pharmaceutical interventions in a

57 similar timeframe as those already in place for influenza prevention.

## 58 **Introduction** (2492 / 3000 Words)

59           The Coronavirus Disease (COVID-19) pandemic has caused unprecedented worldwide  
60 morbidity, mortality, and social and economic disruption. Globally, waves of disease have  
61 primarily corresponded with the emergence of new variants of concern—which have shown  
62 increased transmissibility,<sup>1</sup> improved ability to evade vaccine- or infection-induced immunity,<sup>2</sup>  
63 or both. Vaccination strategies to date have struggled to keep pace, and booster doses have been  
64 deployed to bolster protection against infection and symptomatic disease and maintain peak  
65 levels of protection against severe disease throughout the pandemic.<sup>3-7</sup>

66           Nearly all respiratory viruses capable of causing human infection show distinct seasonal  
67 patterns and result in waves of illness during the winter months.<sup>8,9</sup> These patterns are likely  
68 caused by a combination of host, pathogen, and environmental factors, including increased  
69 indoor activity in the winter months and seasonal temperature and humidity fluctuations known  
70 to impact viral stability outside of the host.<sup>8,10-12</sup> To date, there is still speculation about whether  
71 SARS-CoV-2 currently follows—or will follow in the future—similar seasonal patterns.<sup>13-15</sup>  
72 Determining this is critical for public health planning, including informing vaccine policy about  
73 the optimal timing for deploying booster doses. To help answer this urgent public health  
74 question, we evaluated whether rates of COVID-19 in the United States and Europe followed a  
75 seasonal pattern using time series models.

## 77 **Methods**

### 78 *Primary analysis*

79           Data describing daily frequencies of COVID-19 cases were obtained from the public-use  
80 Our World in Data (OWID) website. For analysis purposes, daily data from OWID were

81 aggregated into weeks for the period between weeks ending March 3, 2020, and April 9, 2022.  
82 We calculated rates for the United States and European Union Five countries (EU5; France,  
83 Germany, Italy, Spain, and the United Kingdom) using country-specific estimated population  
84 sizes and report rates per 1,000,000 for new weekly cases during the study period.<sup>16</sup> We further  
85 stratified data from the United States into the four US Census Bureau Regions (Northeast,  
86 Midwest, West, and South).<sup>17</sup>

87 For our primary analysis, we used Twitter's time series decomposition followed by  
88 generalized extreme studentized deviate (GESD) anomaly detection to identify outlying COVID-  
89 19 rates over time.<sup>18</sup> This method has been shown to reliably detect anomalies in other  
90 transmissible infectious diseases.<sup>19-21</sup> This decomposition and anomaly detection method first  
91 decomposes time series data into trend, seasonal, and remainder components. The trend  
92 component is extracted using piecewise medians and median absolute deviations, which are  
93 appropriate for weekly seasonality and multimodal observed data.<sup>18</sup> After decomposition,  
94 anomalies were detected using GESD, which does not require *a priori* specification of the  
95 number of outliers (as many other outlier tests do), but instead requires the specification of a  
96 range for what should be considered non-outlying data points.<sup>22</sup> We specified a 95% normal  
97 range ( $\alpha = 0.05$ ) with a maximum of 30% of the data to be detected as anomalous to balance  
98 the risk of false positives and negatives.

99

### 100 *Sensitivity analyses*

101 To test the robustness of our findings, we performed several sensitivity analyses. First,  
102 we evaluated the impact of choosing different thresholds for the maximum amount of data to be  
103 detected as anomalous (ranging from 1–50%) compared to the base case of 30% for both the US

104 and EU5 OWID data. To determine the impact of the data source, we repeated the primary  
105 analysis (described above) using national COVID-19 case rate data from the US Centers for  
106 Disease Control and Prevention (CDC) instead of US data derived from OWID.<sup>23</sup>

107 In addition to the methodology used in the primary analysis (i.e., Twitter’s time series  
108 decomposition with GESD anomaly detection), we also used Meta’s (previously Facebook)  
109 Prophet<sup>24,25</sup> approach to decompose US time series rates and adjust for potentially confounding  
110 factors in an additive, linear time series. In the Meta Prophet model, we adjusted for the age-  
111 specific proportion of fully vaccinated individuals over time, US holidays, predominant  
112 circulating variant (omicron, delta, or alpha or wild type), and seasonality (weekly and yearly).  
113 US vaccine uptake data were obtained from US CDC.<sup>26</sup> Age-group-specific vaccine uptake data  
114 were collapsed into a single value for each day by calculating a weighted average of the age-  
115 group-specific proportion of the population who was fully vaccinated (i.e., defined as two doses  
116 of mRNA vaccine or one dose of a single dose adenoviral vector vaccine) and corresponding  
117 age-group-specific population size based on 2022 United States Census Bureau estimates.<sup>27</sup>  
118 Binary indicators of US holidays included were specified by the model as regressors based on  
119 calendar day(s). They included New Year’s Day, Martin Luther King Jr. Day, Washington’s  
120 Birthday, Memorial Day, Independence Day (Observed), Independence Day, Labor Day,  
121 Columbus Day, Veterans Day, Thanksgiving, Christmas Day, Christmas Day (Observed), and  
122 New Year’s Day (Observed). We also added holiday effects for two weeks of an annual spring  
123 break (Mar 16, 2020 – Mar 27, 2020; Mar 15, 2021 – Mar 26, 2021; and Mar 14, 2022 – Mar 25,  
124 2022) and extra days before Christmas Day through New Year’s Day to account for potential  
125 significant holiday travel effects (Dec 21, 2020 – Jan 3, 2021; and Dec 20, 2021 – Jan 2, 2022).  
126 SARS-CoV-2 variant frequencies by date for the United States were obtained from

127 covariants.org.<sup>28</sup> Variant frequencies were summed by week to match COVID-19 case data.  
128 Primary circulating variant was defined as the most frequent variant identified each week and  
129 was categorized into three groups: wild type/Wuhan or alpha (Mar 9, 2020 – Apr 4, 2021), delta  
130 (Apr 5, 2021 – Dec 13, 2021), or omicron (Dec 14, 2021 – Apr 9, 2022). In the Prophet model,  
131 weekly and yearly seasonality were set to automatic detection, while daily seasonality was turned  
132 off as we only had daily reports that were not time-stamped. Uncertainty interval widths were set  
133 to 95%, with 2,000 uncertainty samples used to compute the intervals. Markov chain Monte  
134 Carlo simulations (n=1,000) were used to calculate uncertainty intervals for the Prophet time  
135 series decomposed components.

136 Finally, as a confirmatory sensitivity analysis, we applied both the anomaly detection and  
137 Prophet modeling approaches to US influenza data (rather than COVID-19 data) to assess the  
138 model would predict well-known seasonal patterns for influenza. Influenza case counts for the  
139 United States were obtained from US CDC FluView and included weekly case counts of  
140 influenza viruses reported to CDC through the National Respiratory and Enteric Virus  
141 Surveillance System at the national level.<sup>29</sup> Total influenza cases was defined as the sum of all  
142 subtypes reported to clinical and public health laboratories from Mar 2, 2014, through Apr 5,  
143 2020. We excluded 2020/2021 and 2021/2022 influenza seasons due to the confounding effects  
144 of COVID-19 precautions on reducing the influenza burden.<sup>30</sup>

145 For anomaly detection, a base case of 30% maximum anomalies was used, and for  
146 Prophet modeling, US holidays, the primary circulating variant of the week, and the weekly  
147 population weighted mean of percent vaccine uptake were used for adjustment as indicated  
148 above for COVID-19 data. R version 4.1.2 (R Foundation for Statistical Computing, Vienna,  
149 Austria) was used for all analyses.



150 **Results**

151 Anomaly plots detected COVID-19 rates that were higher than expected between  
152 November and March each year in the United States (**Figure 1A**) and EU5 (**Figure 1B**). In the  
153 United States, trends were similar for the North, Midwest, and West US Census Bureau Regions,  
154 with seasonal spikes in rates observed between November and February (**Figures 2A-2C**). In the  
155 Southern Region, in addition to seasonal peaks in the fall/winter, a second peak in the late  
156 summer of 2021 was identified as anomalous in Aug/Sep 2021, which returned to normal by Oct  
157 2021 (**Figure 2D**). This peak was not identified in the US Southern Region in 2020.

158 Sensitivity analyses confirmed that the threshold for percent of observations detected as  
159 anomalous (supplementary appendix, **Figures s1 – s12**) had little impact on observed seasonal  
160 trends. In addition, seasonal US COVID-19 trends were similar if US CDC data were used  
161 instead of data from OWID (**Figure s13**). Sensitivity analyses using Meta’s Prophet model also  
162 showed a strong annual seasonal component for COVID-19 case rates from approximately  
163 December through February in the United States (**Figure 3A**), similar to the primary analysis.  
164 During the study period, the general trend of COVID-19 was increasing (**Figure 3B**), although  
165 with wide uncertainty intervals. Several strong holiday effects were identified near Christmas  
166 and New Year’s, spring break, and Independence Day (**Figure 3C**).

167 Anomaly detection analyses using the same model specifications described for rates of  
168 COVID-19 also accurately predicted seasonal spikes of influenza between November and April  
169 over six US influenza seasons (**Figure 4**), consistent with current knowledge about annual  
170 influenza patterns in the United States.<sup>31</sup> Further, Prophet modeling of influenza data showed  
171 remarkably similar trends as for COVID-19 (**Figures s14 – s17**), with slightly more residual  
172 variation, likely due to fewer regressors added to the model compared to COVID-19 data.

## 173 Discussion

174 Although SARS-CoV-2 continues to circulate and cause disease year-round, we  
175 identified clear seasonal trends in rates of COVID-19 in the United States and Europe. Since the  
176 beginning of the pandemic, COVID-19 rates in the United States and EU5 have spiked in the  
177 months of December through March—the same months typical of seasonal respiratory virus  
178 epidemics in the northern hemisphere.<sup>31</sup> These results are consistent with other coronaviruses  
179 that exhibit largely seasonal patterns<sup>32</sup> and mathematical simulations of COVID-19 disease  
180 activity.<sup>13,14</sup> There are many possible reasons for seasonality of respiratory viruses, including  
181 climate-related changes in viral transmissibility, modified host factors (e.g., waning of infection-  
182 or vaccine-induced immunity), and changes in human behavior during the winter months.<sup>8,15</sup>  
183 Regardless of the mechanisms, knowledge of pathogen seasonality is imperative for instituting  
184 targeted interventions to decrease disease burden.

185 Accordingly, our findings have important vaccine policy implications. Booster doses of  
186 COVID-19 vaccines administered before the winter months will likely have the most significant  
187 public health impact on COVID-19 disease burden. This is analogous to providing influenza  
188 vaccine before peak flu activity each year. Because SARS-CoV-2 is considerably more  
189 transmissible than influenza and other seasonal respiratory viruses, it remains possible that year-  
190 round SARS-CoV-2 activity will remain elevated compared to other pathogens. Providing more  
191 than one booster dose of COVID-19 vaccines each year, however, has proven programmatically  
192 challenging, and concerns regarding “booster fatigue” are increasing.<sup>33,34</sup> Thus, timing the  
193 administration of an annual COVID-19 vaccine, and thus peak vaccine protection, with the likely  
194 timing of peak COVID-19 disease activity (i.e., the winter viral respiratory season based on our  
195 results) may be the most prudent approach in the near term. Despite evidence that protection

196 provided by current mRNA COVID-19 vaccines wanes significantly against omicron infection  
197 and symptomatic disease after only 3 to 4 months—even after a booster<sup>4,7,35</sup>—this short-term  
198 protection could still provide meaningful defense against SARS-CoV-2 infection if deployed just  
199 before seasonal waves that last 3 to 4 months on average. Moreover, it remains unknown  
200 whether variant-adapted vaccines may improve durability of protection against infection and  
201 symptomatic disease for even longer than current wild-type formulations. Whether additional  
202 boosters at a frequency greater than once annually are needed for some high-risk groups will  
203 likely be a careful balance between epidemiological, benefit-risk, and programmatic  
204 considerations moving forward.

205         There has been much debate about whether the goal of vaccination programs should be  
206 only to prevent severe disease or if it should include preventing infection and reducing  
207 transmission.<sup>36</sup> We now know that vaccination alone is unlikely to lead to the eradication or  
208 elimination of SARS-CoV-2. However, deploying vaccines on schedule that times peak  
209 protection to correspond with peak disease activity can still have a meaningful impact on  
210 flattening future waves of infection and disease in addition to ensuring protection against severe  
211 illness is maintained year-over-year. Lessening the burden of SARS-CoV-2 infection remains an  
212 important goal and corresponds with fewer long-term consequences of infection such as post-  
213 acute sequelae<sup>37-39</sup> and other disruptive societal and economic consequences.<sup>40</sup>

214         A more nuanced finding from our study was that, in the United States, southern States  
215 might be experiencing second summer waves, as has been previously suggested.<sup>41</sup> There could  
216 be many reasons behind this additional summer wave. Some possible explanations include lower  
217 vaccination rates or use of nonpharmaceutical interventions in southern US States compared to  
218 other regions,<sup>42</sup> changes in behavioral patterns including end-of-summer vacations to southern

219 States, or increased indoor gathering due to excessive heat during this time in the US south.  
220 Visually, there were slight increases in rates within other US Census regions during this time,  
221 however, they were within the expected variability of case rates. It is reasonable to assume that  
222 there would have been higher rates during these months in all regions had adequate protections  
223 (e.g., vaccination, nonpharmaceutical interventions) been less prevalent.

224 In sensitivity analyses, our methodology accurately detected anomalous rates of influenza  
225 virus infection in the United States, underscoring the utility of anomaly detection for detecting  
226 seasonal patterns in common respiratory viruses. Although the ‘influenza season’ appeared to be  
227 slightly longer than the ‘COVID-19 season,’ this could be due to the additional prevention  
228 measures taken for COVID-19, including masking and social distancing. These interventions are  
229 highly effective for influenza, as evidenced by the near disappearance of influenza infection  
230 during the height of the COVID-19 pandemic in the United States.<sup>30</sup>

231 Our results have limitations. First, we could not account for potential underreporting of  
232 cases, which may have a large effect more recently with increases in at-home SARS-CoV-2  
233 testing that may not be reported.<sup>43</sup> Further, statistical modeling may not fully reflect the  
234 intricacies of preventing transmissible infectious diseases, such as the impact of waning  
235 immunity or changes in testing, nonpharmaceutical interventions, or healthcare-seeking behavior  
236 over time. Despite this, our sensitivity analysis using Meta’s Prophet model, which controlled for  
237 vaccination coverage over time, holidays, and the dominant SARS-CoV-2 variant each week,  
238 also showed a strong annual seasonal component for rates of COVID-19. Moreover, we found  
239 seasonal patterns over the duration of the entire pandemic despite changes in testing and  
240 mitigation behaviors over time. Although the pandemic is in its third year, the amount of data  
241 available for forecasting was limited compared to other common seasonal viruses. Because of

242 this, forecasts may change rapidly in the months or years ahead. Another limitation is that our  
243 findings are not generalizable beyond the United States and Europe, and more research is needed  
244 to understand if seasonal patterns in SARS-CoV-2 activity are seen in the Southern Hemisphere  
245 or Asia-Pacific regions. Finally, with SARS-CoV-2, there is always the potential for new  
246 variants to emerge that could meaningfully escape prior vaccine- or infection-induced immunity  
247 and cause epidemics outside of regular seasonal patterns. Thus, the public health community  
248 should continue to plan and maintain capability for this possibility.

249         Although SARS-CoV-2 continues to cause morbidity and mortality year-round due to its  
250 high transmissibility and continued rapid viral evolution, our results suggest that COVID-19  
251 activity in the United States and Europe peaks during the traditional winter viral respiratory  
252 season. Thus, employing annual protective measures against SARS-CoV-2 such as administering  
253 seasonal booster vaccines or other non-pharmaceutical interventions in a similar timeframe as  
254 those already in place for influenza prevention (i.e., beginning in early autumn) is a prudent  
255 strategy to stay ahead of likely forthcoming seasonal waves of COVID-19. Additional  
256 confirmatory studies including those conducted in the Southern Hemisphere and other regions  
257 outside of the United States and Europe, however, are needed.  
258

259 **Acknowledgments**

260 **Author Contributions:** Dr. Wiemken had full access to all the data in the study and took  
261 responsibility for the integrity and data analysis accuracy. All authors had full access to all data  
262 and accept responsibility for submitting for publication.

263 *Concept and design:* All Authors.

264 *Accessed and verified data and analysis:* TLW, FK

265 *Interpretation of data:* All authors.

266 *Drafting of the manuscript:* TLW, JMM

267 *Critical revision of the manuscript for important intellectual content:* All Authors

268 *Obtained funding:* N/A.

269 *Administrative, technical, or material support:* All Authors

270 *Supervision:* JMM

271

272 **Conflict of Interest Disclosures:** Drs. Wiemken, Nguyen, Jodar, and McLaughlin and Mr. Khan  
273 are employees and shareholders of Pfizer Inc.

274

275 **Funding/Support:** Pfizer, Inc

276

277 **Role of the Funder/Sponsor:** This study was sponsored by Pfizer.

278 **Data Sharing:** All data utilized in this study are open and available to the public free of charge,  
279 as referenced.

280 **REFERENCES**

- 281 1. Centers for Disease Control and Prevention. COVID-19: Omicron Variant: What You  
282 Need to Know. <https://www.cdc.gov/coronavirus/2019-ncov/variants/omicron-variant.html>  
283 (accessed March 7, 2022).
- 284 2. Thorne LG, Bouhaddou M, Reuschl AK, et al. Evolution of enhanced innate immune  
285 evasion by SARS-CoV-2. *Nature* 2022; **602**(7897): 487-95.
- 286 3. Bar-On YM, Goldberg Y, Mandel M, et al. Protection by a Fourth Dose of BNT162b2  
287 against Omicron in Israel. *N Engl J Med* 2022.
- 288 4. Ferdinands JM, Rao S, Dixon BE, et al. Waning 2-Dose and 3-Dose Effectiveness of  
289 mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care  
290 Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant  
291 Predominance - VISION Network, 10 States, August 2021-January 2022. *MMWR Morb Mortal*  
292 *Wkly Rep* 2022; **71**(7): 255-63.
- 293 5. Tartof SY, Slezak JM, Puzniak L, et al. Effectiveness of a third dose of BNT162b2  
294 mRNA COVID-19 vaccine in a large US health system: A retrospective cohort study. *Lancet*  
295 *Reg Health Am* 2022: 100198.
- 296 6. Thompson MG, Natarajan K, Irving SA, et al. Effectiveness of a Third Dose of mRNA  
297 Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters  
298 and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance  
299 - VISION Network, 10 States, August 2021-January 2022. *MMWR Morb Mortal Wkly Rep* 2022;  
300 **71**(4): 139-45.


- 301 7. Tartof SY, Slezak JM, Puzniak L, et al. Immunocompromise and durability of BNT162b2  
302 vaccine against severe outcomes due to omicron and delta variants. *Lancet Respiratory Medicine*  
303 2022.
- 304 8. Moriyama M, Hugentobler WJ, Iwasaki A. Seasonality of Respiratory Viral Infections.  
305 *Annu Rev Virol* 2020; **7**(1): 83-101.
- 306 9. Hawkes MT, Lee BE, Kanji JN, et al. Seasonality of Respiratory Viruses at Northern  
307 Latitudes. *JAMA Netw Open* 2021; **4**(9): e2124650.
- 308 10. Biryukov J, Boydston JA, Dunning RA, et al. Increasing Temperature and Relative  
309 Humidity Accelerates Inactivation of SARS-CoV-2 on Surfaces. *mSphere* 2020; **5**(4).
- 310 11. Grohskopf LA, Alyanak E, Ferdinands JM, et al. Prevention and Control of Seasonal  
311 Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization  
312 Practices, United States, 2021-22 Influenza Season. *MMWR Recomm Rep* 2021; **70**(5): 1-28.
- 313 12. Lowen AC, Steel J. Roles of humidity and temperature in shaping influenza seasonality. *J*  
314 *Virol* 2014; **88**(14): 7692-5.
- 315 13. Liu X, Huang J, Li C, et al. The role of seasonality in the spread of COVID-19 pandemic.  
316 *Environ Res* 2021; **195**: 110874.
- 317 14. Merow C, Urban MC. Seasonality and uncertainty in global COVID-19 growth rates.  
318 *Proc Natl Acad Sci U S A* 2020; **117**(44): 27456-64.
- 319 15. Choi YW, Tuel A, Eltahir EAB. On the Environmental Determinants of COVID-19  
320 Seasonality. *Geohealth* 2021; **5**(6): e2021GH000413.
- 321 16. Worldmeter. Countries in the world by population (2022). 2022.  
322 <https://www.worldometers.info/world-population/population-by-country/> (accessed April 29,  
323 2022.




- 324 17. United States Census Bureau. Census Regions and Divisions of the United States.  
325 [https://www2.census.gov/geo/pdfs/maps-data/maps/reference/us\\_regdiv.pdf](https://www2.census.gov/geo/pdfs/maps-data/maps/reference/us_regdiv.pdf) (accessed May 5,  
326 2022).
- 327 18. Vallis O, Hochenbaum J, Kejariwal A. A novel technique for long-term anomaly  
328 detection in the cloud. 6th USENIX Workshop on Hot Topics in Cloud Computing.  
329 Philadelphia, PA; 2014.
- 330 19. Wiemken TL, Rutschman AS, Niemotka S, Prener CG. Excess mortality in the United  
331 States in 2020: Forecasting and anomaly detection. *Am J Infect Control* 2021; **49**(9): 1189-90.
- 332 20. Wiemken TL, Rutschman AS, Niemotka SL, Hoft D. Thresholds versus Anomaly  
333 Detection for Surveillance of Pneumonia and Influenza Mortality. *Emerg Infect Dis* 2020;  
334 **26**(11): 2733-5.
- 335 21. Wiemken TL, Furmanek SP, Mattingly WA, et al. Methods for computational disease  
336 surveillance in infection prevention and control: Statistical process control versus Twitter's  
337 anomaly and breakout detection algorithms. *Am J Infect Control* 2018; **46**(2): 124-32.
- 338 22. US Department of Commerce NIfSaT. Engineering Statistics Handbook: 1.3.5.17.3.  
339 Generalized ESD Test for Outliers  
340  
341 . <https://www.itl.nist.gov/div898/handbook/eda/section3/eda35h3.htm> (accessed May 4, 2022).
- 342 23. Centers for Disease Control and Prevention. COVID Data Tracker: COVID-19 Weekly  
343 Cases and Deaths per 100,000 Population by Age, Race/Ethnicity, and Sex. 2022.  
344 <https://covid.cdc.gov/covid-data-tracker/#demographicsovertime> (accessed May 11, 2022).
- 345 24. Taylor S, Letham B. Forecasting at scale. *Peer J Preprints* 2017; **5**: e3190v2.
- 346 25. Taylor S, Letham B. prophet: Automatic Forecasting Procedure. 1.0 ed; 2021.

- 347 26. Centers for Disease Control and Prevention. COVID-19 Vaccination and Case Trends by  
348 Age Group, United States. 2022. [https://data.cdc.gov/Vaccinations/COVID-19-Vaccination-and-](https://data.cdc.gov/Vaccinations/COVID-19-Vaccination-and-Case-Trends-by-Age-Group-/gxj9-t96f)  
349 [Case-Trends-by-Age-Group-/gxj9-t96f](https://data.cdc.gov/Vaccinations/COVID-19-Vaccination-and-Case-Trends-by-Age-Group-/gxj9-t96f) (accessed April 26, 2022).
- 350 27. United States Census Bureau. 2017 National Population Projections Datasets. February  
351 20, 2020 2021. <https://www.census.gov/data/datasets/2017/demo/popproj/2017-popproj.html>  
352 (accessed August 24, 2021).
- 353 28. Hodcroft E. CoVariants. 2022. <https://covariants.org> (accessed April 14, 2022).
- 354 29. Centers for Disease Control and Prevention. FluView Flu Activity and Surveillance.  
355 2022. <https://gis.cdc.gov/grasp/fluview/fluportaldashboard.html> (accessed May 4, 2022).
- 356 30. Wiemken TL, Shacham E. Identifying potential undocumented COVID-19 using publicly  
357 reported influenza-like-illness and laboratory-confirmed influenza disease in the United States:  
358 An approach to syndromic surveillance? *Am J Infect Control* 2020; **48**(8): 961-3.
- 359 31. Centers for Disease Control and Prevention. Influenza (flu): Flu Season. September 28,  
360 2021. <https://www.cdc.gov/flu/about/season/flu-season.htm> (accessed April 25, 2022).
- 361 32. Nichols GL, Gillingham EL, Macintyre HL, et al. Coronavirus seasonality, respiratory  
362 infections and weather. *BMC Infect Dis* 2021; **21**(1): 1101.
- 363 33. University of Minnesota Center for Infectious Diseases Research and Policy. CDC  
364 advisers discuss future of COVID-19 booster shots. April 20, 2022 2022.  
365 [https://www.cidrap.umn.edu/news-perspective/2022/04/cdc-advisers-discuss-future-covid-19-](https://www.cidrap.umn.edu/news-perspective/2022/04/cdc-advisers-discuss-future-covid-19-booster-shots)  
366 [booster-shots](https://www.cidrap.umn.edu/news-perspective/2022/04/cdc-advisers-discuss-future-covid-19-booster-shots) (accessed May 17, 2022).
- 367 34. Oliver S. Framework for future doses of COVID-19 vaccine doses and next steps. April  
368 20, 2022 2022. [https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2022-04-20/07-](https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2022-04-20/07-COVID-Oliver-508.pdf)  
369 [COVID-Oliver-508.pdf](https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2022-04-20/07-COVID-Oliver-508.pdf) (accessed May 17, 2022).

- 370 35. Tartof SY, Slezak JM, Puzniak L, et al. BNT162b2 (Pfizer–Biontech) mRNA COVID-19  
371 Vaccine Against Omicron-Related Hospital and Emergency Department Admission in a Large  
372 US Health System: A Test-Negative Design. *SSRN Pre Print* 2022.
- 373 36. Korpar L. COVID Hospitalization Data Should Be Focus Rather Than Daily Case  
374 Counts: Experts. *Newsweek*. January 4, 2022.
- 375 37. Gupta A, Madhavan MV, Sehgal K, et al. Extrapulmonary manifestations of COVID-19.  
376 *Nat Med* 2020; **26**(7): 1017-32.
- 377 38. Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. *Nat Med* 2021;  
378 **27**(4): 601-15.
- 379 39. Mehandru S, Merad M. Pathological sequelae of long-haul COVID. *Nat Immunol* 2022;  
380 **23**(2): 194-202.
- 381 40. Yeyati E, Filippini F. Social and economic impact of COVID-19. June 8, 2021.  
382 <https://www.brookings.edu/research/social-and-economic-impact-of-covid-19/> (accessed May  
383 12, 2022).
- 384 41. News C. Transcript: Dr. Deborah Birx on “Face the Nation” May 1, 2022. 2022.
- 385 42. The PEW Charitable Trusts. 10 States Have School Mask Mandates While 8 Forbid  
386 Them. August 10, 2021 2022. [https://www.pewtrusts.org/en/research-and-](https://www.pewtrusts.org/en/research-and-analysis/blogs/stateline/2021/08/10/10-states-have-school-mask-mandates-while-8-forbid-them)  
387 [analysis/blogs/stateline/2021/08/10/10-states-have-school-mask-mandates-while-8-forbid-them](https://www.pewtrusts.org/en/research-and-analysis/blogs/stateline/2021/08/10/10-states-have-school-mask-mandates-while-8-forbid-them)  
388 (accessed May 6, 2022).
- 389 43. Rader B, Gertz A, Iuliano AD, et al. Use of At-Home COVID-19 Tests - United States,  
390 August 23, 2021-March 12, 2022. *MMWR Morb Mortal Wkly Rep* 2022; **71**(13): 489-94.  
391






**Figure 2:** Twitter time series decomposition with generalized extreme studentized deviate (GESD) anomaly detection of COVID-19 rates, Mar 7, 2020 – Apr 9, 2022, United States, by Census Region.

**Panel A,** Northeast Region; **Panel B,** Midwest Region; **Panel C,** West Region; **Panel D,** South Region.  
Data Source: Our World in Data


394  
395



**Figure 3:** COVID-19 rates from the Prophet decomposed model with Markov chain Monte Carlo Simulated 95% uncertainty intervals, Mar 7, 2020 – Apr 9, 2022, adjusted for US holidays, dominant variant, and age-weighted vaccine uptake, United States.

**Panel A:** Annual seasonal component aggregated over study period; **Panel B,** Trend Component; **Panel C,** Holiday Component; **Panel D,** Residual Component. Data Source: Our World in Data

396  
397



**Figure 4:** Twitter time series decomposition with generalized extreme studentized deviate (GESD) anomaly detection of Influenza cases, Mar 1, 2014 – Apr 10, 2020. Shaded areas represent the normal range of data points. Data Source: United States Centers for Disease Control and Prevention FluView

## Supplementary Appendix

for

Is COVID-19 seasonal? A time series modeling approach



## Table of Content

Figure s1. Twitter time series decomposition with generalized extreme studentized deviate (GESD) anomaly detection of US COVID-19 case rates, Mar 7, 2020 – Apr 9, 2022, with 1% maximum anomalies, Data Source: OWID .....	4
Figure s2. Twitter time series decomposition with generalized extreme studentized deviate (GESD) anomaly detection of EU-5 Country COVID-19 case rates, Mar 7, 2020 – Apr 9, 2022, with 1% maximum anomalies, Data Source: OWID.....	5
Figure s3. Twitter time series decomposition with generalized extreme studentized deviate (GESD) anomaly detection of US COVID-19 case rates, Mar 7, 2020 – Apr 9, 2022, with 5% maximum anomalies, Data Source: OWID .....	6
Figure s4. Twitter time series decomposition with generalized extreme studentized deviate (GESD) anomaly detection of EU-5 Country COVID-19 case rates, Mar 7, 2020 – Apr 9, 2022, with 5% maximum anomalies, Data Source: OWID.....	7
Figure s5. Twitter time series decomposition with generalized extreme studentized deviate (GESD) anomaly detection of US COVID-19 case rates, Mar 7, 2020 – Apr 9, 2022, with 10% maximum anomalies, Data Source: OWID .....	8
Figure s6. Twitter time series decomposition with generalized extreme studentized deviate (GESD) anomaly detection of EU-5 Country COVID-19 case rates, Mar 7, 2020 – Apr 9, 2022, with 10% maximum anomalies, Data Source: OWID.....	9
Figure s7. Twitter time series decomposition with generalized extreme studentized deviate (GESD) anomaly detection of US COVID-19 case rates, Mar 7, 2020 – Apr 9, 2022, with 20% maximum anomalies, Data Source: OWID .....	10
Figure s8. Twitter time series decomposition with generalized extreme studentized deviate (GESD) anomaly detection of EU-5 Country COVID-19 case rates, Mar 7, 2020 – Apr 9, 2022, with 20% maximum anomalies, Data Source: OWID.....	11
Figure s9. Twitter time series decomposition with generalized extreme studentized deviate (GESD) anomaly detection of US COVID-19 case rates, Mar 7, 2020 – Apr 9, 2022, with 40% maximum anomalies, Data Source: OWID .....	12
Figure s10. Twitter time series decomposition with generalized extreme studentized deviate (GESD) anomaly detection of EU-5 Country COVID-19 case rates, Mar 7, 2020 – Apr 9, 2022, with 40% maximum anomalies, Data Source: OWID.....	13
Figure s11. Twitter time series decomposition with generalized extreme studentized deviate (GESD) anomaly detection of US COVID-19 case rates, Mar 7, 2020 – Apr 9, 2022, with 50% maximum anomalies, Data Source: OWID .....	14
Figure s12. Twitter time series decomposition with generalized extreme studentized deviate (GESD) anomaly detection of EU-5 Country COVID-19 case rates, Mar 7, 2020 – Apr 9, 2022, with 50% maximum anomalies, Data Source: OWID.....	15

Figure s13. Twitter time series decomposition with generalized extreme studentized deviate (GESD) anomaly detection of US COVID-19 case rates, Mar 7, 2020 – Apr 9, 2022, with 30% maximum anomalies, Data Source: US CDC .....	16
Figure s14. Seasonal component of Influenza cases from the Prophet decomposed model with Markov chain Monte Carlo Simulated 95% uncertainty intervals, Mar 1, 2014 – Apr 10, 2020, holiday-adjusted, United States. Data Source: US CDC .....	17
Figure s15. Holiday component of Influenza cases from the Prophet decomposed model with Markov chain Monte Carlo Simulated 95% uncertainty intervals, Mar 1, 2014 – Apr 10, 2020, holiday-adjusted, United States. Data Source: US CDC .....	18
Figure s16. Trend component of Influenza cases from the Prophet decomposed model with Markov chain Monte Carlo Simulated 95% uncertainty intervals, Mar 1, 2014 – Apr 10, 2020, holiday-adjusted, United States. Data Source: US CDC .....	19
Figure s17. Residual component of Influenza cases from the Prophet decomposed model with Markov chain Monte Carlo Simulated 95% uncertainty intervals, Mar 1, 2014 – Apr 10, 2020, holiday-adjusted, United States. Data Source: US CDC .....	20




Figure s1. Twitter time series decomposition with generalized extreme studentized deviate (GESD) anomaly detection of US COVID-19 case rates, Mar 7, 2020 – Apr 9, 2022, with 1% maximum anomalies, Data Source: OWID




Figure s2. Twitter time series decomposition with generalized extreme studentized deviate (GESD) anomaly detection of EU-5 Country COVID-19 case rates, Mar 7, 2020 – Apr 9, 2022, with 1% maximum anomalies, Data Source: OWID




Figure s3. Twitter time series decomposition with generalized extreme studentized deviate (GESD) anomaly detection of US COVID-19 case rates, Mar 7, 2020 – Apr 9, 2022, with 5% maximum anomalies, Data Source: OWID




Figure s4. Twitter time series decomposition with generalized extreme studentized deviate (GESD) anomaly detection of EU-5 Country COVID-19 case rates, Mar 7, 2020 – Apr 9, 2022, with 5% maximum anomalies, Data Source: OWID




Figure s5. Twitter time series decomposition with generalized extreme studentized deviate (GESD) anomaly detection of US COVID-19 case rates, Mar 7, 2020 – Apr 9, 2022, with 10% maximum anomalies, Data Source: OWID




Figure s6. Twitter time series decomposition with generalized extreme studentized deviate (GESD) anomaly detection of EU-5 Country COVID-19 case rates, Mar 7, 2020 – Apr 9, 2022, with 10% maximum anomalies, Data Source: OWID






Figure s7. Twitter time series decomposition with generalized extreme studentized deviate (GESD) anomaly detection of US COVID-19 case rates, Mar 7, 2020 – Apr 9, 2022, with 20% maximum anomalies, Data Source: OWID




Figure s8. Twitter time series decomposition with generalized extreme studentized deviate (GESD) anomaly detection of EU-5 Country COVID-19 case rates, Mar 7, 2020 – Apr 9, 2022, with 20% maximum anomalies, Data Source: OWID




Figure s9. Twitter time series decomposition with generalized extreme studentized deviate (GESD) anomaly detection of US COVID-19 case rates, Mar 7, 2020 – Apr 9, 2022, with 40% maximum anomalies, Data Source: OWID




Figure s10. Twitter time series decomposition with generalized extreme studentized deviate (GESD) anomaly detection of EU-5 Country COVID-19 case rates, Mar 7, 2020 – Apr 9, 2022, with 40% maximum anomalies, Data Source: OWID




Figure s11. Twitter time series decomposition with generalized extreme studentized deviate (GESD) anomaly detection of US COVID-19 case rates, Mar 7, 2020 – Apr 9, 2022, with 50% maximum anomalies, Data Source: OWID




Figure s12. Twitter time series decomposition with generalized extreme studentized deviate (GESD) anomaly detection of EU-5 Country COVID-19 case rates, Mar 7, 2020 – Apr 9, 2022, with 50% maximum anomalies, Data Source: OWID






Figure s13. Twitter time series decomposition with generalized extreme studentized deviate (GESD) anomaly detection of US COVID-19 case rates, Mar 7, 2020 – Apr 9, 2022, with 30% maximum anomalies, Data Source: US CDC




*Figure s14. Seasonal component of Influenza cases from the Prophet decomposed model with Markov chain Monte Carlo Simulated 95% uncertainty intervals, Mar 1, 2014 – Apr 10, 2020, holiday-adjusted, United States. Data Source: US CDC*






*Figure s15. Holiday component of Influenza cases from the Prophet decomposed model with Markov chain Monte Carlo Simulated 95% uncertainty intervals, Mar 1, 2014 – Apr 10, 2020, holiday-adjusted, United States. Data Source: US CDC*



*Figure s16. Trend component of Influenza cases from the Prophet decomposed model with Markov chain Monte Carlo Simulated 95% uncertainty intervals, Mar 1, 2014 – Apr 10, 2020, holiday-adjusted, United States. Data Source: US CDC*



*Figure s17. Residual component of Influenza cases from the Prophet decomposed model with Markov chain Monte Carlo Simulated 95% uncertainty intervals, Mar 1, 2014 – Apr 10, 2020, holiday-adjusted, United States. Data Source: US CDC*